Kelley, R. K., Sangro, B., Harris, W., Ikeda, M., Okusaka, T., Kang, Y., Qin, S., Tai, D. W., Lim, H. Y., Yau, T., Yong, W., Cheng, A., Gasbarrini, A., Damian, S., Bruix, J., Borad, M., Bendell, J., Kim, T., Standifer, N., He, P., Makowsky, M., Negro, A., Kudo, M., & Abou-Alfa, G. K. (2021). safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. Journal of clinical oncology, 39(27), 2991–3001. http://access.bl.uk/ark:/81055/vdc_100150610061.0x000032